Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025
Rhea-AI Summary
Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has announced its upcoming participation at The Citizens Life Sciences Conference.
The company's management will deliver a presentation on Wednesday, May 7, 2025, at 12:30 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the "Events" section of Sionna's investor relations website at investors.sionnatx.com.
Sionna's mission centers on revolutionizing CF treatment by developing new medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The presentation recording will remain accessible on the company's website for 90 days following the event.
Positive
- Clinical-stage biotech company with focus on cystic fibrosis treatment innovation
- Development of novel CFTR protein-targeting medicines indicates potential market opportunity
Negative
- None.
News Market Reaction
On the day this news was published, SION declined 0.08%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 12:30 p.m. ET.
A live webcast of the presentation will be available the day of the event on the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will be available for 90 days following the event.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
FAQ
When will Sionna Therapeutics (SION) present at The Citizens Life Sciences Conference 2025?
How can I watch Sionna Therapeutics' (SION) presentation at the Citizens Conference 2025?
What is Sionna Therapeutics' (SION) main focus in cystic fibrosis treatment?
How long will Sionna Therapeutics' (SION) May 2025 conference presentation replay be available?
What stage is Sionna Therapeutics (SION) at in developing CF treatments?
